Coherus BioSciences Inc. (NASDAQ: CHRS)
$1.80
+0.1450 ( +8.79% ) 2.1M
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Market Data
Open
$1.80
Previous close
$1.65
Volume
2.1M
Market cap
$206.51M
Day range
$1.66 - $1.80
52 week range
$1.25 - $5.47
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jan 23, 2024 |
4 | Insider transactions | 1 | Jan 23, 2024 |
8-k | 8K-related | 15 | Jan 22, 2024 |
8-k | 8K-related | 15 | Jan 10, 2024 |
8-k | 8K-related | 13 | Jan 10, 2024 |
4 | Insider transactions | 1 | Jan 09, 2024 |
4 | Insider transactions | 1 | Jan 08, 2024 |
4 | Insider transactions | 1 | Jan 08, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |
4 | Insider transactions | 1 | Jan 04, 2024 |